Metformin inhibits estrogen‐dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway

@inproceedings{Zou2016MetforminIE,
  title={Metformin inhibits estrogen‐dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway},
  author={Jingfang Zou and Liangli Hong and Chaohuan Luo and Zhi Li and Yuzhang Zhu and Tianliang Huang and Yongneng Zhang and Huier Yuan and Yaqiu Hu and Tengfei Wen and Wanling Zhuang and Bozhi Cai and Xin Zhang and Jiexiong Huang and Jidong Cheng},
  booktitle={Cancer science},
  year={2016}
}
Metformin is an oral biguanide commonly used for treating type II diabetes and has recently been reported to possess antiproliferative properties that can be exploited for the prevention and treatment of a variety of cancers. The mechanisms underlying this effect have not been fully elucidated. Our study shows a marked loss of AMP-activated protein kinase (AMPK) phosphorylation and nuclear human Forkhead box O1 (FOXO1) protein in estrogen-dependent endometrial cancer (EC) tumors compared to… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Metformin as a Therapeutic Target in Endometrial Cancers

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The regulation of FOXO1 and its role in disease progression.

Ya-Qi Xing, Ang Li, +3 authors Hui-Cai Guo
  • Life sciences
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 61 REFERENCES

obese women with type I endometrial cancer is associated with a reduced incidence of cancer recurrence

EL Greer, D Dowlatshahi, MR Banko
  • Int J Gynecol Cancer
  • 2016

formin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy

K Bhalla, BJ Hwang, RE Dewi
  • Mol Cancer Ther
  • 2013

Similar Papers

Loading similar papers…